Skip to main content
Premium Trial:

Request an Annual Quote

Biden Looks to Continue Cancer Work

Vice President Joe Biden plans to continue his cancer work after leaving the White House, the Washington Post reports.

Biden is currently heading up the cancer moonshot initiative announced by President Barack Obama in his last State of the Union Address in 2016 that aims to increase cancer research funding and break down barriers between different cancer research silos. The recently passed 21st Century Cures Act includes some $1.8 billion for the effort.

Biden tells the Post that that his new nonprofit organization will tackle many of the same data sharing and clinical trial participation issues as the moonshot effort, but also others like drug pricing.

"I'm going to begin a national conversation and get Congress and advocacy groups in to make sure these treatments are accessible for everyone, including these vulnerable underserved populations, and that we have a more rational way of paying for them while promoting innovation," Biden tells the Post. Biden's son Beau died of brain cancer in 2015.

He adds that the nonprofit, tentatively being called the Biden Cancer Initiative, will be located in either Washington, DC, or Wilmington, Del., and won't be associated with any cancer center.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.